CONFLUENCE Trademark

Trademark Overview

On Friday, September 1, 2023, a trademark application was filed for CONFLUENCE with the United States Patent and Trademark Office. The USPTO has given the CONFLUENCE trademark a serial number of 98161571. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, December 6, 2024. This trademark is owned by Aclaris Therapeutics, Inc.. The CONFLUENCE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research in the field of pharmaceuticals and biotechnology; drug discovery services; drug discovery consulting services; medical and scientific research consulting services in the field of drug discovery and pharmaceutical drug development; providing medical and scientific research, namely, assay design and validation and biomarker assessment

General Information

Serial Number98161571
Word MarkCONFLUENCE
Filing DateFriday, September 1, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, December 6, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesResearch and development in the pharmaceutical and biotechnology fields; providing medical and scientific research in the field of pharmaceuticals and biotechnology; drug discovery services; drug discovery consulting services; medical and scientific research consulting services in the field of drug discovery and pharmaceutical drug development; providing medical and scientific research, namely, assay design and validation and biomarker assessment

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, September 27, 2023
Primary Code042
First Use Anywhere DateThursday, August 3, 2017
First Use In Commerce DateThursday, August 3, 2017

Trademark Owner History

Party NameAclaris Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWayne, PA 19087

Trademark Events

Event DateEvent Description
Tuesday, September 5, 2023NEW APPLICATION ENTERED
Wednesday, September 27, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, November 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, November 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, April 30, 2024ASSIGNED TO EXAMINER
Friday, May 3, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, May 3, 2024NON-FINAL ACTION E-MAILED
Friday, May 3, 2024NON-FINAL ACTION WRITTEN
Tuesday, July 30, 2024TEAS AMENDMENT OF USE RECEIVED
Tuesday, July 30, 2024USE AMENDMENT FILED
Tuesday, July 30, 2024AMENDMENT TO USE PROCESSING COMPLETE
Wednesday, July 31, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 31, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 31, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sunday, August 25, 2024USE AMENDMENT ACCEPTED
Monday, August 26, 2024NON-FINAL ACTION WRITTEN
Monday, August 26, 2024NON-FINAL ACTION E-MAILED
Monday, August 26, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, November 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, December 6, 2024NON-FINAL ACTION WRITTEN
Friday, December 6, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, December 6, 2024NON-FINAL ACTION E-MAILED

Related Keywords

confluence research drug discovery services medical scientific pharmaceutical development consulting providing